No Cure No Pay incassobureau (NCNP) strategy could be an answer to tensions between the drug industry and health authorities.
It is a simple but effective approach that benefits the authorities, the industry and, ultimately, the patients. It provides a clear incentive for rational pharmacotherapy by increasing the financial reward for drugs that work and by reducing payments for ineffective ones.
No Pay Direct Debit: What You Need to Know
The concept is based on the principle of the standard form of salvage contract known as Lloyd’s Open Form, or LOF, which was established in 1908. The term “no cure no pay” means that only if successful salvage is made is payment due to the salvor. A similar principle could be applied to pharmaceutical marketing. It is not a cheap marketing technique, and a broad application would probably mean a reduction in the number of sales representatives. It also requires the cooperation of healthcare staff and political decision makers. These are all challenges that need to be addressed before the strategy can be expanded.